GSK said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

Every woman has a one in 87 chance of getting ovarian cancer in her lifetime, and one in 130 will die from it. The symptoms ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

A number of ovarian cancer vaccines are being evaluated including the world's first cancer prevention vaccine, which recently ...

GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...

Study analyzed global patterns and trends in ovarian cancer incidence from 1988 to 2017, highlighting variations by ...

Jayden Whyman met his future wife, Tasha, at a bus stop in Rotorua when they were just teenagers. She loved painting, walking ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...

Sophie Casey, 28, was diagnosed with stage 4B Ovarian cancer in October and is now raising awareness of the disease ...

Sophie Casey, 28, told how doctors thought she had an infection when her stomach started swelling up but warned others about the risk of being “fobbed off” by doctors ...

An MRI-based imaging technique developed at the University of Cambridge could be used to predict the response of ovarian ...